乳房切除是否联合乳房再造的肿瘤安全性与并发症风险:贝叶斯分析
该系统评价与贝叶斯网络分析纳入51项研究共265,522例患者,比较单纯乳房切除(MA)、即刻乳房再造(IBR)与延迟乳房再造(DBR)的肿瘤安全性与并发症风险。结果显示,IBR或DBR与MA相比总生存期更优,IBR较MA远处转移率更低,但IBR总体并发症和手术部位感染风险高于其他两组。
要点
- 乳房再造(IBR或DBR)未对肿瘤安全性产生不利影响。
- IBR较MA总体并发症及手术部位感染风险更高。
- IBR较MA远处转移率更低,DBR与IBR总生存期优于MA。
核心结论
- 乳房再造无论即刻或延迟均不 adversely 影响乳腺癌患者的肿瘤安全性。
- IBR与总体并发症及手术部位感染风险增加相关。
研究设计与样本
- 共纳入51项研究,265,522例患者,比较MA、IBR与DBR三组的肿瘤安全性与并发症风险。
主要发现
- DBR vs. MA总生存期OR 4.12(95% CrI 1.80-10.01);IBR vs. MA总生存期OR 1.75(95% CrI 1.32-2.32)。
- IBR vs. MA远处转移率OR 0.67(95% CrI 0.51-0.90)。
- 总体并发症IBR vs. DBR的OR 1.40(95% CrI 1.01-1.93)。
- 手术部位感染IBR vs. MA的OR 1.77(95% CrI 1.03-3.13)。
临床怎么用
- 乳腺癌乳房切除患者选择再造时,应告知IBR增加总体并发症及手术部位感染风险。
- IBR或DBR不增加肿瘤学风险,可作为肿瘤安全的手术选项。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Currently, breast cancer patients undergoing mastectomy (MA) have three surgical options: MA only and reconstruction at the time of MA ("immediate," IBR) or at a later time ("delayed," DBR). To assess the oncological safety and complication risks associated with different surgical choices, a systematic review with Bayesian network analysis was conducted. METHODS: Cochrane library, PubMed/MEDLINE, EMBASE, and the China National Knowledge Infrastructure were systematically searched in November 2019. The odds ratios [OR] were estimated for oncological safety (including disease-free survival, overall survival, local recurrence, and distant metastases) and complication risks (including overall complications, surgical site infection, and lymphedema) among MA, IBR, and DBR groups. RESULTS: In the included 51 studies (265,522 patients), reconstruction after MA for IBR or DBR was associated with increased overall survival compared to simple MA (DBR vs. MA: OR 4.12, 95% credible interval [CrI] 1.80-10.01; IBR vs. MA: OR 1.75, 95% CrI 1.32-2.32). Additionally, IBR was associated with a decreased distant metastasis rate compared to MA (IBR vs. MA: OR 0.67, 95% CrI 0.51-0.90). However, the risk of overall complications and surgical site infection was higher in the IBR group than in the other two groups (complications, IBR vs. DBR: OR 1.40, 95% CrI 1.01-1.93; surgical site infection, IBR vs. MA: OR 1.77, 95% CrI 1.03-3.13). CONCLUSIONS: Evidence suggested that breast reconstruction, whether IBR or DBR, does not adversely affect oncological safety in the setting of breast cancer. IBR is associated with an increased risk of overall complications and surgical site infection, but technical advances in this surgical procedure have cumulated over time.
引用
- Shen Z, Sun J, Yu Y, et al. Oncological safety and complication risks of mastectomy with or without breast reconstruction: A Bayesian analysis. J Plast Reconstr Aesthet Surg. 2020. PMID: 33093010. doi:10.1016/j.bjps.2020.08.121
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。